Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 3Completed 2Suspended 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Glioblastoma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × TPI-287 × Clear all
NCT02047214 2018-01-31

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Cortice Biosciences, Inc.

Phase 2 Terminated
17 enrolled
CNS

Glioblastoma

NCT00479635 2014-01-22

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Cortice Biosciences, Inc.

Phase 2 Terminated
26 enrolled
Genitourinary

Prostatic Neoplasms

NCT00553813 2014-01-22

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

Cortice Biosciences, Inc.

Phase 2 Terminated
23 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡